Paper41354809
Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives.
Ma X and 6 others. J Ovarian Res, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives. Papers, record 41354809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41354809
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives.
- PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ovarian Neoplasms | Major topic |
| Humans | |
| Female | |
| Immunotherapy |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| No.82160552 | the National Natural Science Foundation of China | PubMed | ||
| 2024B001 | the Health Commission of Jilin Province | PubMed | ||
| 202501-202912 | the transverse project | PubMed |
Source PubMed
References151
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37802375 | Guizhi Fuling Formulation: A review on chemical constituents, quality control, pharmacokinetic studies, pharmacological properties, adverse reactions and clinical applications. | J Ethnopharmacol | 2024 | https://conductscience.org/library/papers/37802375 | PubMed |
| 2 | 33584699 | Dendritic Cell Vaccines in Ovarian Cancer. | Front Immunol | 2020 | https://conductscience.org/library/papers/33584699 | PubMed |
| 3 | 36331779 | Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids. | Drugs | 2022 | https://conductscience.org/library/papers/36331779 | PubMed |
| 4 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 5 | 35816189 | Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35816189 | PubMed |
| 6 | 28039265 | Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28039265 | PubMed |
| 7 | 32132244 | Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer. | Microbiol Mol Biol Rev | 2020 | https://conductscience.org/library/papers/32132244 | PubMed |
| 8 | 36902470 | Ovarian Cancer and Glutamine Metabolism. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36902470 | PubMed |
| 9 | 38862154 | Investigating age and ethnicity as novel high-risk phenotypes in mucinous ovarian cancer: retrospective study in a multi-ethnic population. | Int J Gynecol Cancer | 2024 | https://conductscience.org/library/papers/38862154 | PubMed |
| 10 | 29107691 | Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism. | Biochem Biophys Res Commun | 2018 | https://conductscience.org/library/papers/29107691 | PubMed |
| 11 | 38388177 | Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass. | Int J Gynecol Cancer | 2024 | https://conductscience.org/library/papers/38388177 | PubMed |
| 12 | 39659585 | Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer. | Theranostics | 2024 | https://conductscience.org/library/papers/39659585 | PubMed |
| 13 | 35264436 | Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35264436 | PubMed |
| 14 | 38777849 | The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/38777849 | PubMed |
| 15 | 34479871 | Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34479871 | PubMed |
| 16 | 38223825 | Ginsenoside 20(S)-Rg3 reduces KIF20A expression and promotes CDC25A proteasomal degradation in epithelial ovarian cancer. | J Ginseng Res | 2024 | https://conductscience.org/library/papers/38223825 | PubMed |
| 17 | 40928736 | Global, regional, and national burden of ovarian cancer, 1990-2021, and projections to 2050: a cross-sectional analysis of the Global Burden of Disease Study 2021. | Int J Surg | 2026 | https://conductscience.org/library/papers/40928736 | PubMed |
| 18 | 19723649 | A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19723649 | PubMed |
| 19 | 34860006 | Cancer-Erythrocyte Hybrid Membrane-Camouflaged Magnetic Nanoparticles with Enhanced Photothermal-Immunotherapy for Ovarian Cancer. | ACS Nano | 2021 | https://conductscience.org/library/papers/34860006 | PubMed |
| 20 | 38565643 | Short-chain fatty acids: linking diet, the microbiome and immunity. | Nat Rev Immunol | 2024 | https://conductscience.org/library/papers/38565643 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42957658 | Cell death-based treatment of ovarian cancer. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42957658 | PubMed |
| 42907928 | From cytoreduction to precision oncology: evolution of ovarian cancer therapy. | J Ovarian Res | 2026 | https://conductscience.org/library/papers/42907928 | PubMed |
| 42877886 | Stimulator of Interferon Genes (STING) Agonist-Loaded Copper-Based Nanoparticles for B7-H3 Blockade-Enhanced Chemodynamic-Immunotherapy of Ovarian Cancer. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42877886 | PubMed |
| 42819173 | Mechanisms of resistance to PARP inhibitors in advanced epithelial ovarian cancer: biological determinants and therapeutic implications. | Front Oncol | 2026 | https://conductscience.org/library/papers/42819173 | PubMed |
| 42649936 | Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649936 | PubMed |
| 42590851 | Methotrexate Alters Nrf2/HO-1 Protein Expression and Intrinsic Apoptosis-Associated Protein Responses in OVCAR-3 Ovarian Cancer Cells: Differential Modulation by Antioxidant Compounds. | J Biochem Mol Toxicol | 2026 | https://conductscience.org/library/papers/42590851 | PubMed |
| 42587603 | Discovery and Development of a TGFβ3/IL-13 Plasma Risk Score for Preoperative Discrimination of Benign and Malignant Ovarian Adnexal Masses. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42587603 | PubMed |
| 42070192 | Deciphering the potential pathogenic mechanisms of 3-BHA in ovarian cancer through integrated bioinformatics and machine learning strategies. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42070192 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41354809
GET https://conductscience.org/api/papers/v1/41354809/references?page=2